CDNF rescues motor neurons in models of amyotrophic lateral sclerosis by targeting endoplasmic reticulum stress

• Published in: Brain (London, England : 1878) Vol. 146; no. 9; pp. 3783 - 3799
• Main Authors: De Lorenzo, Francesca, Lüningschrör, Patrick, Nam, Jinhan, Beckett, Liam, Pilotto, Federica, Galli, Emilia, Lindholm, Päivi, Rüdt von Collenberg, Cora, Mungwa, Simon Tii, Jablonka, Sibylle, Kauder, Julia, Thau-Habermann, Nadine, Petri, Susanne, Lindholm, Dan, Saxena, Smita, Sendtner, Michael, Saarma, Mart, Voutilainen, Merja H
• Format: Journal Article
• Language: English
• Published: US Oxford University Press 01.09.2023
• Subjects: Amyotrophic Lateral Sclerosis - metabolism; Animals; Choline O-Acetyltransferase - metabolism; Choline O-Acetyltransferase - pharmacology; Choline O-Acetyltransferase - therapeutic use; Disease Models, Animal; Dopamine - metabolism; Endoplasmic Reticulum Stress; Endoribonucleases - metabolism; Endoribonucleases - pharmacology; Endoribonucleases - therapeutic use; Mice; Motor Neurons - metabolism; Nerve Growth Factors - metabolism; Neurodegenerative Diseases - metabolism; Original; Protein Serine-Threonine Kinases - metabolism; Rats; Superoxide Dismutase-1 - genetics; motor neurons; ER stress; unfolded protein response; amyotrophic lateral sclerosis; CDNF
• ISSN: 0006-8950; 1460-2156
• DOI: 10.1093/brain/awad087

Abstract Amyotrophic lateral sclerosis is a progressive neurodegenerative disease that affects motor neurons in the spinal cord, brainstem and motor cortex, leading to paralysis and eventually to death within 3–5 years of symptom onset. To date, no cure or effective therapy is available. The role of chronic endoplasmic reticulum stress in the pathophysiology of amyotrophic lateral sclerosis, as well as a potential drug target, has received increasing attention. Here, we investigated the mode of action and therapeutic effect of the endoplasmic reticulum-resident protein cerebral dopamine neurotrophic factor in three preclinical models of amyotrophic lateral sclerosis, exhibiting different disease development and aetiology: (i) the conditional choline acetyltransferase-tTA/TRE-hTDP43-M337V rat model previously described; (ii) the widely used SOD1-G93A mouse model; and (iii) a novel slow-progressive TDP43-M337V mouse model. To specifically analyse the endoplasmic reticulum stress response in motor neurons, we used three main methods: (i) primary cultures of motor neurons derived from embryonic Day 13 embryos; (ii) immunohistochemical analyses of spinal cord sections with choline acetyltransferase as spinal motor neuron marker; and (iii) quantitative polymerase chain reaction analyses of lumbar motor neurons isolated via laser microdissection. We show that intracerebroventricular administration of cerebral dopamine neurotrophic factor significantly halts the progression of the disease and improves motor behaviour in TDP43-M337V and SOD1-G93A rodent models of amyotrophic lateral sclerosis. Cerebral dopamine neurotrophic factor rescues motor neurons in vitro and in vivo from endoplasmic reticulum stress-associated cell death and its beneficial effect is independent of genetic disease aetiology. Notably, cerebral dopamine neurotrophic factor regulates the unfolded protein response initiated by transducers IRE1α, PERK and ATF6, thereby enhancing motor neuron survival. Thus, cerebral dopamine neurotrophic factor holds great promise for the design of new rational treatments for amyotrophic lateral sclerosis. De Lorenzo et al. report that intracerebroventricular administration of cerebral dopamine neurotrophic factor protects motor neurons, improves motor behaviour and delays disease progression in three rodent models of ALS.